von Marco Nassisi ; Giuseppe De Bartolo ; Saddek Mohand-Said ; Christel Condroyer ; Aline Antonio ; Marie-Elise Lancelot ; Kinga Bujakowska ; Vasily Smirnov ; Thomas Pugliese ; John Neidhardt ; José-Alain Sahel ; Christina Zeitz ; Isabelle Audo
This study reports characteristics and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (aNSCLC) receiving nivolumab in second-line or later (2L+) in France and Germany between 2015 and 2020. Patients with aNSCLC (stage IIIB-C/IV) receiving nivolumab in 2L+ were included from the retrospective Epidemiological Strategy and Medical Economics of Advanced and Metastatic Lung Cancer cohort (ESME-AMLC, France; 2015-2019) and Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP, Germany; 2016-2020). Overall, 2262 ESME-AMLC and 522 CRISP patients were included. Median treatment duration (95% confidence intervals) was 2.8 months (2.5-3.2) in squamous and 2.5 months (2.3-2.8) in non-squamous/others patients in ESME-AMLC, and 2.3 months (1.4-3.1) and 2.3 months (2.0-2.8), respectively in CRISP. One-year and two-year overall survival (OS) were 47.2% and 26.7% in squamous and 50.8% and 32.8% in non-squamous/others patients in ESME-AMLC, and 43.1% and 20.9%, and 37.7% and 18.9%, respectively in CRISP. Poorer performance score and shorter time from start of previous line of therapy initiation were significantly associated with shorter treatment duration and OS. This study confirms, in real-world clinical databases, the efficacy of nivolumab previously observed in clinical trials.
von Frank Griesinger ; Maurice Pérol ; Nicolas Girard ; Isabelle Durand-Zaleski ; Stefan Zacharias ; Lise Bosquet ; Martina Jänicke ; Xavier Quantin ; Annika Groth ; Annette Fleitz ; Alan Calleja ; Sonya Patel ; Laure Lacoin ; Melinda J. Daumont ; John R. Penrod ; Robert Carroll ; Daniela Waldenberger ; Dorothée Reynaud ; Michael Thomas ; Christos Chouaid
Objectives - To describe the impact of immune checkpoint inhibitors (ICIs) on treatment patterns and survival outcomes in patients with locally advanced or metastatic non-small cell lung cancer (aNSCLC) in France and Germany. - Materials and Methods - Patients with aNSCLC without known ALK or EGFR mutations receiving first-line (1L) therapy were included from (i) the retrospective Epidemiological-Strategy and Medical Economics Advanced and Metastatic Lung Cancer cohort (ESME-AMLC, France; 2015-2018) and (ii) the prospective Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients platform (CRISP, Germany; 2016-2018). Analyses were stratified according to histology. Survival outcomes were estimated using Kaplan-Meier methodology and stratified by year of 1L therapy. Data sources were analysed separately. - Results - In ESME-AMLC and CRISP, 8,046 and 2,359 patients were included in the study, respectively. In both countries, approximately 20 % of all patients received pembrolizumab monotherapy as 1L treatment in 2018. In ESME-AMLC, the proportion receiving an ICI over the course of treatment (any line) increased from 42.2 % (2015) to 56.1 % (2018) in patients with squamous histology, and 28.9 % to 51.9 % with non-squamous/other; in CRISP, it increased from 50.6 % (2016) to 65.2 % (2018) with squamous histology, and 40.8 % to 62.7 % with non-squamous/other. Two-year overall survival from 1L initiation was 36.8 % and 25.6 % in the squamous cohorts and 36.5 % and 30.8 % in the non-squamous/other cohorts in ESME-AMLC and CRISP, respectively. No significant change in overall survival was observed over time; however, the follow-up time available was limited in the later years of the analysis. - Conclusion - The results of this joint research from two large clinical databases in France and Germany demonstrate the growing use of ICIs in the management of aNSCLC. Future analyses will allow for the evaluation of the impact of ICIs on long-term survival of patients with aNSCLC.
Lung cancer Amsterdam [u.a.] : Elsevier, 1985 172(2022) vom: Okt., Seite 65-74 Online-Ressource
von Hamsa Ahmed ; Mohamed Elshabasi ; Marco A. González ; Michael Richter ; Marko Stölzel ; Alfons Weber ; Stephan John Heise ; Thomas Dalibor ; Sascha Schäfer ; Jürgen Parisi
von Sandra Díaz ; Jens Kattge ; Johannes H. C. Cornelissen ; Ian J. Wright ; Sandra Lavorel ; Stéphane Dray ; Björn Reu ; Michael Kleyer ; Vanessa Minden ; Gerhard Zotz
von Hamsa Ahmed ; Mohamed Elshabasi ; Jörg Ohland ; Marko Stölzel ; Alfons Weber ; Robert W. Lechner ; Thomas Dalibor ; Jürgen Parisi ; Sascha Schäfer ; Stephan John Heise
von Hamsa Ahmed ; Vita Solovyeva ; Marco A. González ; Mohamed Elshabasi ; Michael Richter ; Devendra Pareek ; Stephan John Heise ; Marko Stölzel ; Alfons Weber ; Thomas Dalibor ; Sascha Schäfer ; Jürgen Parisi
Seite 2 von 5
